drugset
Drugs / REGN5713
last change Jan 2026 re-read 3 minutes ago

REGN5713

Monoclonal antibody

Developed for
conjunctivitis · allergic rhinitis
Investigated by
Regeneron Pharmaceuticals

Trials 4

today NCT07309432 · Ph 3 NCT06602739 · Ph 3 NCT05430919 · Ph 2 NCT04709575 · Ph 3
2021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial · 1 met primary
Phase 2 NCT05430919 Aug 2022 → Jul 2023 allergic rhinitis, conjunctivitis Regeneron Pharmaceuticals Completed Met primary
Phase 33 trials · 2 met primary
Phase 3 NCT07309432 Jan 2026 → Feb 2027 expected conjunctivitis Regeneron Pharmaceuticals Recruiting No outcome recorded
Phase 3 NCT06602739 Nov 2024 → Apr 2025 conjunctivitis Regeneron Pharmaceuticals Completed Met primary
Phase 3 NCT04709575 Jan → Aug 2021 allergic rhinitis, conjunctivitis Regeneron Pharmaceuticals Completed Met primary

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2025-09-08 Regeneron Pharmaceuticals Results Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies regeneron.com ↗
The primary endpoint of ocular itch and both key secondary endpoints of conjunctival redness and skin prick testing – assessed one week after the single treatment with BetV1-blocking antibodies – were met with high degree of statistical significance.

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as REGN5713 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07309432 ↗
3

NCT06602739 ↗

NCT05430919 ↗

NCT04709575 ↗
Modality Monoclonal antibody “Anti-Bet v 1 Monoclonal Antibodies” NCT05430919 ↗
Route Subcutaneous “REGN5713-5714-5715 administered subcutaneously” NCT04709575 ↗